2023年6月最新SCI影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | ENDOCRINE-RELATED CANCER ENDOCR-RELAT CANCER （此期刊被最新的JCR期刊SCIE收录） LetPub评分 7.4
50人评分
我要评分
声誉 8.8 影响力 6.5 速度 7.0 | |||||||||||||||||||||||||||||
| 期刊ISSN | 1351-0088 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||||||
| 2022-2023最新影响因子 （数据来源于搜索引擎） | 3.9 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||
| 实时影响因子 | 截止2023年9月27日：2.532 | |||||||||||||||||||||||||||||
| 2022-2023自引率 | 2.60%点击查看自引率趋势图 | |||||||||||||||||||||||||||||
| 五年影响因子 | 5.1 | |||||||||||||||||||||||||||||
| h-index | 119 | |||||||||||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||||||||||
| 期刊简介 | Endocrine-Related Cancer is an official flagship journal of the Society for Endocrinology and is endorsed by the European Society of Endocrinology, the United Kingdom and Ireland Neuroendocrine Society, and the Japanese Hormones and Cancer Society. Endocrine-Related Cancer provides a unique international forum for the publication of high quality original articles describing novel, cutting edge basic laboratory, translational and clinical investigations of human health and disease focusing on endocrine neoplasias and hormone-dependent cancers; and for the publication of authoritative review articles in these topics. Endocrine neoplasias include adrenal cortex, breast, multiple endocrine neoplasia, neuroendocrine tumours, ovary, prostate, paraganglioma, parathyroid, pheochromocytoma pituitary, testes, thyroid and hormone-dependent cancers. Neoplasias affecting metabolism and energy production such as bladder, bone, kidney, lung, and head and neck, are also considered. | |||||||||||||||||||||||||||||
| 期刊官方网站 | http://erc.endocrinology-journals.org/ | |||||||||||||||||||||||||||||
| 期刊投稿网址 | http://www.endocrinology-journals.org/site/misc/submit-online.xhtml | |||||||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足ENDOCRINE-RELATED CANCER的语言要求，还能让ENDOCRINE-RELATED CANCER编辑和审稿人得到更好的审稿体验，让稿件最大限度地被ENDOCRINE-RELATED CANCER编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||||||||||
| 通讯方式 | BIOSCIENTIFICA LTD, EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL, ENGLAND, BS324JT | |||||||||||||||||||||||||||||
| 出版商 | BioScientifica Ltd. | |||||||||||||||||||||||||||||
| 涉及的研究方向 | 医学-内分泌学与代谢 | |||||||||||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||
| 出版周期 | Quarterly | |||||||||||||||||||||||||||||
| 出版年份 | 1994 | |||||||||||||||||||||||||||||
| 年文章数 | 73点击查看年文章数趋势图 | |||||||||||||||||||||||||||||
| Gold OA文章占比 | 13.86% | |||||||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 80.82% | |||||||||||||||||||||||||||||
| WOS期刊SCI分区 （ 2022-2023年最新版） | WOS分区等级：2区
| |||||||||||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1351-0088%5BISSN%5D | |||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 较慢,6-12周 | |||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 一般 | |||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在ENDOCRINE-RELATED CANCER顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | TAGLN2 promotes papillary thyroid carcinoma invasion via the Rap1/PI3K/AKT axis Author: Wang, Lidong; Tan, Hao; Huang, Yonglian; Guo, Mingyue; Dong, Yanxu; Liu, Chenxi; Zhao, Huai; Liu, Zhen Journal: ENDOCRINE-RELATED CANCER. 2023; Vol. 30, Issue 1, pp. -. DOI: 10.1530/ERC-21-0352 PubMed DOI |
| 2. | The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma Author: Li, Wenwen; Wang, Teng; Fu, Guobin; Xu, Yuan; Zhang, Nasha; Han, Linyu; Yang, Ming Journal: ENDOCRINE-RELATED CANCER. 2023; Vol. 30, Issue 1, pp. -. DOI: 10.1530/ERC-22-0189 PubMed DOI |
| 3. | Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation Author: Hu, Chunyan; Wang, Manli; Hu, Miao; Ma, Shanshan; Yang, Bingmo; Xiao, Wei; Zhou, Qian; Zhou, Ming; Li, Zhong Journal: ENDOCRINE-RELATED CANCER. 2023; Vol. 30, Issue 2, pp. -. DOI: 10.1530/ERC-22-0191 PubMed DOI |
| 4. | Cell diversity and immune infiltration in the parathyroid tumour microenvironment Author: Zhang, Xiang; Hu, Ya; Cui, Ming; Wang, Mengyi; Li, Xiaobin; Zhang, Yalu; Yang, Sen; Hua, Surong; Shen, Meiping; Liao, Quan Journal: ENDOCRINE-RELATED CANCER. 2023; Vol. 30, Issue 3, pp. -. DOI: 10.1530/ERC-22-0325 PubMed DOI |
| 5. | Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer Author: Liu, Xiaoli; Zhang, Chunhai; Wang, Xiaomiao; Cui, Can; Cui, Hanwen; Zhu, Baishu; Chen, Anqi; Zhang, Lu; Xin, Jingwei; Fu, Qingfeng; Dionigi, Gianlorenzo; Sun, Hui Journal: ENDOCRINE-RELATED CANCER. 2023; Vol. 30, Issue 3, pp. -. DOI: 10.1530/ERC-22-0221 PubMed DOI |
| 6. | Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ. Author: Xekouki P1,2, Lodge EJ1,3, Matschke J4, Santambrogio A1,5, Apps JR6,7, Sharif A8, Jacques TS6,7, Aylwin S2, Prevot V8, Li R9, Flitsch J10, Bornstein SR3,5, Theodoropoulou M11, Andoniadou CL1,5. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):215-225. doi: 10.1530/ERC-18-0330. PubMed DOI |
| 7. | Antitumor effects of anlotinib in thyroid cancer. Author: Ruan X1, Shi X2, Dong Q2, Yu Y1, Hou X1, Song X2, Wei X3, Chen L2, Gao M1. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):153-164. doi: 10.1530/ERC-17-0558. PubMed DOI |
| 8. | KLF14 potentiates oxidative adaptation via modulating HO-1 signaling in castrate-resistant prostate cancer. Author: Luo XH1, Liu JZ1, Wang B1, Men QL1, Ju YQ1, Yin FY1, Zheng C1, Li W2. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):181-195. doi: 10.1530/ERC-18-0383. PubMed DOI |
| 9. | Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. Author: Guan W1, Hu J1,2,3, Yang L4, Tan P4, Tang Z4, West BL5, Bollag G5, Xu H1, Wu L3,6,7,8,9. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):131-140. doi: 10.1530/ERC-18-0284. PubMed DOI |
| 10. | ATM deficiency promotes progression of CRPC by enhancing Warburg effect. Author: Xu L1,2, Ma E3, Zeng T2,4, Zhao R5, Tao Y2, Chen X2, Groth J2, Liang C1, Hu H2,6, Huang J2,6,7. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):59-71. doi: 10.1530/ERC-18-0196. PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共1条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
